Melissa L. Johnson, MD - Harnessing the Potential of HER2-, HER3-, and TROP2-Targeted Therapies to Address Unmet Needs in Advanced NSCLC

Go online to PeerView.com/ANP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for NSCLC with and without genomic alterations is continuously growing, and novel HER2-, HER3-, and TROP2-targeting antibody–drug conjugates, among other agents, are showing great promise for improving outcomes in challenging subgroups of patients with lung cancer. Extensive and nuanced biomarker testing has never been more important in guiding the integration of an expanding array of current and emerging targeted therapies into practice. This PeerView Live MasterClass based on a recent live web broadcast provides evidence-based expert instruction on the evolving best practices for biomarker testing, as well as the rapidly accumulating evidence base on and clinical implications of recent advances with HER2-, HER3-, and TROP2-targeted therapies in the modern era of precision lung cancer care. Upon completion of this accredited CE activity, participants should be better able to: Review the frequency, clinical importance, and biologic rationale for targeting HER2, HER3, and TROP2 alterations with novel therapies in lung cancer, Describe the current guidelines and best practices for biomarker testing in patients with NSCLC, Summarize the characteristics, mechanisms of action, latest safety and efficacy findings, and recommendations of emerging HER2-, HER3-, and TROP2-targeted therapies in NSCLC, Integrate individualized treatment plans through different lines of therapy for patients with NSCLC that take into consideration appropriate strategies for biomarker testing/interpretation to identify patients with NSCLC who might benefit from emerging HER2-, HER3-, and TROP2-targeted therapies.